AU2003222896A1 - Pharmaceutical composition which improves in vivo gene transfer - Google Patents

Pharmaceutical composition which improves in vivo gene transfer

Info

Publication number
AU2003222896A1
AU2003222896A1 AU2003222896A AU2003222896A AU2003222896A1 AU 2003222896 A1 AU2003222896 A1 AU 2003222896A1 AU 2003222896 A AU2003222896 A AU 2003222896A AU 2003222896 A AU2003222896 A AU 2003222896A AU 2003222896 A1 AU2003222896 A1 AU 2003222896A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
improves
gene transfer
vivo gene
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003222896A
Other languages
English (en)
Other versions
AU2003222896A8 (en
Inventor
Bruno Pitard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Santé et de la Recherche Médicale
Original Assignee
Institut National de la Santé et de la Recherche Médicale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Santé et de la Recherche Médicale filed Critical Institut National de la Santé et de la Recherche Médicale
Publication of AU2003222896A1 publication Critical patent/AU2003222896A1/en
Publication of AU2003222896A8 publication Critical patent/AU2003222896A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2003222896A 2002-02-08 2003-02-07 Pharmaceutical composition which improves in vivo gene transfer Abandoned AU2003222896A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0201584A FR2835749B1 (fr) 2002-02-08 2002-02-08 Composition pharmaceutique ameliorant le transfert de gene in vivo
FR02/01584 2002-02-08
PCT/FR2003/000407 WO2003066104A2 (fr) 2002-02-08 2003-02-07 Composition pharmaceutique ameliorant le transfert de gene in vivo

Publications (2)

Publication Number Publication Date
AU2003222896A1 true AU2003222896A1 (en) 2003-09-02
AU2003222896A8 AU2003222896A8 (en) 2003-09-02

Family

ID=27620039

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003222896A Abandoned AU2003222896A1 (en) 2002-02-08 2003-02-07 Pharmaceutical composition which improves in vivo gene transfer

Country Status (10)

Country Link
US (2) US7709452B2 (cg-RX-API-DMAC7.html)
EP (1) EP1471944B1 (cg-RX-API-DMAC7.html)
JP (1) JP4613011B2 (cg-RX-API-DMAC7.html)
AT (1) ATE326986T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003222896A1 (cg-RX-API-DMAC7.html)
CA (1) CA2473212C (cg-RX-API-DMAC7.html)
DE (1) DE60305443T2 (cg-RX-API-DMAC7.html)
ES (1) ES2265569T3 (cg-RX-API-DMAC7.html)
FR (1) FR2835749B1 (cg-RX-API-DMAC7.html)
WO (1) WO2003066104A2 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868953B1 (fr) * 2004-04-16 2006-06-30 Inst Nat Sante Rech Med Composition pour le transfert intracellulaire d'un acide nucleique.
CA2662520A1 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties
DE102006051623A1 (de) 2006-11-02 2008-07-31 Horn, Peter A. Verfahren und Stoffgemisch zur Verbesserung eines in vivo Genfransfers
EP2331071A1 (en) 2008-09-05 2011-06-15 Institut National De La Sante Et De La Recherche Medicale Novel multimodular assembly useful for intracellular delivery
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013106558A1 (en) 2012-01-10 2013-07-18 Merial Limited Lipid based adjuvants for dna - plasmid vaccines
WO2013128424A1 (en) 2012-03-02 2013-09-06 Institut National De La Sante Et De La Recherche Medicale Vaccine for prophylaxis or treatment of an allergen-driven and/or a chronic airways disease
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US20150182620A1 (en) 2012-06-15 2015-07-02 Inserm (Institut De La Sante Et De La Recherche Medicale) Polypeptides for use in the Prophylactic Treatment of Allergic Asthma
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
EP3125945B1 (en) * 2014-04-01 2019-09-11 Institut National de la Sante et de la Recherche Medicale (INSERM) Capped and uncapped rna molecules and block copolymers for intracellular delivery of rna
EP3225246A1 (en) 2016-03-31 2017-10-04 Klinikum der Universität München Synthetic compound for improving efficiency of transfection
US20210000917A1 (en) 2018-03-05 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and composition for the treatment of allergic asthma
CA3131824A1 (en) * 2019-03-11 2020-09-17 Birgitte Rono Nucleic acid vaccination using neo-epitope encoding constructs
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy
WO2024200831A1 (en) 2023-03-30 2024-10-03 Vivadju Pvax14 nucleic acid in combination with all-trans retinoic acid (atra) and a checkpoint inhibitor for the treatment of cancer
EP4704856A1 (en) 2023-03-30 2026-03-11 Vivadju Pvax14 nucleic acid formulated with nano-vehicle in combination with all-trans retinoic acid (atra) for activating immune pathways
WO2025129128A1 (en) 2023-12-15 2025-06-19 Vivasor, Inc. Compositions and methods for non-viral delivery of therapeutic compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470568A (en) * 1992-02-13 1995-11-28 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for cell repair
GB9216082D0 (en) * 1992-07-28 1992-09-09 Univ Nottingham Lymphatic delivery composition
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6359054B1 (en) * 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
EP1038016A2 (en) * 1997-12-16 2000-09-27 Valentis Inc. Needle-free injection of formulated nucleic acid molecules
GB9904627D0 (en) * 1999-03-02 1999-04-21 Danbiosyst Uk Polymer compositions for polynucleotide delivery
WO2001005913A1 (en) 1999-07-16 2001-01-25 Reatech Phosphor addition in gasification
WO2001008709A1 (en) * 1999-07-28 2001-02-08 Valentis, Inc. Sonoporation of tumors
AU2001238485A1 (en) 2000-02-18 2001-08-27 The Immune Response Corporation Methods and compositions for gene delivery
AU2001241958A1 (en) * 2000-03-03 2001-09-17 Valentis, Inc. Improved poloxamer and poloxamine compositions for nucleic acid delivery
DE60144338D1 (de) 2000-10-20 2011-05-12 Vical Inc Gen-abgabeformulierungen zur behandlung ischämischer zustände

Also Published As

Publication number Publication date
WO2003066104A2 (fr) 2003-08-14
US20050152870A1 (en) 2005-07-14
EP1471944B1 (fr) 2006-05-24
US8367631B2 (en) 2013-02-05
US20100179212A1 (en) 2010-07-15
US7709452B2 (en) 2010-05-04
ES2265569T3 (es) 2007-02-16
FR2835749B1 (fr) 2006-04-14
WO2003066104A3 (fr) 2004-03-25
JP2005522433A (ja) 2005-07-28
JP4613011B2 (ja) 2011-01-12
CA2473212C (fr) 2013-04-23
DE60305443D1 (de) 2006-06-29
EP1471944A2 (fr) 2004-11-03
CA2473212A1 (fr) 2003-08-14
FR2835749A1 (fr) 2003-08-15
AU2003222896A8 (en) 2003-09-02
DE60305443T2 (de) 2007-05-10
ATE326986T1 (de) 2006-06-15

Similar Documents

Publication Publication Date Title
AU2003222896A8 (en) Pharmaceutical composition which improves in vivo gene transfer
AU2002236346A1 (en) Environmentally degradable polymeric compounds, their preparation and use as hot melt adhesive
BR0116004A (pt) Derivados de 6-o-carbamoil cetolida de eritromicina úteis como antibacterianos
EP1798231A3 (fr) Produits intermédiaires dans la préparation de composés anti-bactériens
CA2379026A1 (en) Substituted thiene-3-yl-sulphonylamino(thio)carbonyl-triazolin(thi)ones
BR0213802A (pt) Copolìmero útil para a preparação de géis de ácidos
JP2005522433A5 (cg-RX-API-DMAC7.html)
CA2349227A1 (en) Substituted 2-phenylbenzimidazoles, the production thereof and their use
IL152673A0 (en) Nucleotide analogues comprising a reporter moiety and a polymerase enzyme blocking moiety
WO2003066847A3 (en) Phytase variants
WO2006048330A8 (en) 11βετα-hsd1 inhibitors
ATE551988T1 (de) Orale zusammensetzungen, ihre herstellung und verwendung
EP1236754A3 (en) Polyhydroxyalkanoate and method of producing same, and omega-(2-thienylsulfanyl) alkanoic acid and method of producing same
CA2283509A1 (en) Novel bicyclonucleoside and oligonucleotide analogue
WO2007089330A3 (en) Extreme environment surfactant compositions comprising hydrolysis resistant organomodified disiloxane surfactants
BG105736A (en) 2,3,4,5-tetrahydro-1h-[1,4]benzodiasepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
CA2419296A1 (en) New macrolides with antibacterial activity
TW200604158A (en) New sulphur compounds: use as transfer agents for controlled radical polymerisation of acrylic acid, polymers obtained and applications thereof
DE50209545D1 (de) Flüssigkristallines medium
PL345448A1 (en) Substituted phenyl uracils
WO2005052145A3 (en) Recombinant alkaliizing bacteria
EP1152010A3 (en) Oligonucleotide labeling reactants and their use
CA2426613A1 (en) Hydrogelatinizer
IL157241A0 (en) Malic acid addition salts of terbinafine
WO2001010861A3 (de) Substituierte heterocyclyl-2h-chromene

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase